The Price Is Right: Amgen Defends Repatha At $9,669 Against More Critics

Using a higher event rate typical of real-world, high-risk CV patients, Amgen asserts Repatha is cost effective at $9,669, the going discounted rate in the market. But criticism over the PCSK9 inhibitors' cost-effectiveness continues.